文献速递前列腺癌

局限性高强度聚焦超声治疗临床显著非转移性前列腺癌的5年多中心结局

A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
PubMed 文献 · Eur Urol · 2018-06-28

这项前瞻性多中心研究纳入625例临床显著非转移性前列腺癌患者,接受局灶性高强度聚焦超声(HIFU)治疗。中位随访56个月,5年无失败生存率为88%,无转移生存率98%,癌症特异性生存率100%,总生存率99%;241/247例(98%)实现完全无尿垫尿控。局灶HIFU对选择性患者中期有效且副作用概率低。

要点

  • 5年无失败生存率88%,无转移生存率98%,癌症特异性生存率100%。
  • 241/247例(98%)实现完全无尿垫尿控,无患者每日需超过1个尿垫。
  • 中位随访56个月,中位年龄65岁,术前中位PSA 7.2 ng/ml。

核心结论

  • 局灶HIFU治疗选择性临床显著非转移性前列腺癌中期有效,且副作用概率低。

主要发现

  • 中位随访56个月(IQR 35-70),中位年龄65岁(IQR 61-71),术前中位PSA 7.2 ng/ml(IQR 5.2-10.0)。
  • 505例(84%)为中危或高危前列腺癌。
  • 无失败生存率1年99%(95%CI 98-100%),3年92%(95%CI 90-95%),5年88%(95%CI 85-91%)。
  • 5年无转移生存率98%(95%CI 97-99%),癌症特异性生存率100%,总生存率99%(95%CI 97-100%)。
  • 在返回验证问卷的患者中,241/247例(98%)实现完全无尿垫尿控,无患者每日需超过1个尿垫。

临床怎么用

  • 对于选择性临床显著非转移性前列腺癌患者,局灶HIFU可作为全腺体治疗的替代选择,中期肿瘤控制良好且尿控副作用低。

局限性

  • 缺乏长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinically significant nonmetastatic prostate cancer (PCa) is currently treated using whole-gland therapy. This approach is effective but can have urinary, sexual, and rectal side effects. OBJECTIVE: To report on 5-yr PCa control following focal high-intensity focused ultrasound (HIFU) therapy to treat individual areas of cancer within the prostate. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective study of 625 consecutive patients with nonmetastatic clinically significant PCa undergoing focal HIFU therapy (Sonablate) in secondary care centres between January 1, 2006 and December 31, 2015. A minimum of 6-mo follow-up was available for599 patients. Intermediate- or high-risk PCa was found in 505 patients (84%). INTERVENTION: Disease was localised using multiparametric magnetic resonance imaging (mpMRI) combined with targeted and systematic biopsies, or transperineal mapping biopsies. Areas of significant disease were treated. Follow-up included prostate-specific antigen (PSA) measurement, mpMRI, and biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint, failure-free survival (FFS), was defined as freedom from radical or systemic therapy, metastases, and cancer-specific mortality. RESULTS AND LIMITATIONS: The median follow-up was 56 mo (interquartile range [IQR] 35-70). The median age was 65 yr (IQR 61-71) and median preoperative PSA was 7.2 ng/ml (IQR 5.2-10.0). FFS was 99% (95% confidence interval [CI] 98-100%) at 1 yr, 92% (95% CI 90-95%) at 3 yr, and 88% (95% 85-91%) at 5 yr. For the whole patient cohort, metastasis-free, cancer-specific, and overall survival at 5 yr was 98% (95% CI 97-99%), 100%, and 99% (95% CI 97-100%), respectively. Among patients who returned validated questionnaires, 241/247 (98%) achieved complete pad-free urinary continence and none required more than 1 pad/d. Limitations include the lack of long-term follow-up. CONCLUSIONS: Focal therapy for select patients with clinically significant nonmetastatic prostate cancer is effective in the medium term and has a low probability of side effects. PATIENT SUMMARY: In this multicentre study of 625 patients undergoing focal therapy using high-intensity focused ultrasound (HIFU), failure-free survival, metastasis-free survival, cancer-specific survival, and overall survival were 88%, 98%, 100%, and 99%, respectively. Urinary incontinence (any pad use) was 2%. Focal HIFU therapy for patients with clinically significant prostate cancer that has not spread has a low probability of side effects and is effective at 5 yr.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Guillaumier S, Peters M, Arya M, et al. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. Eur Urol. 2018. PMID: 29960750. doi:10.1016/j.eururo.2018.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。